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Abstract
Fibroblast growth factor 21 (FGF21) has recently emerged as a metabolic hormone involved in regulating glucose and lipid
metabolism in mouse, but the regulatory mechanisms and actions of FGF21 in humans remain unclear. Here we have
investigated the regulatory mechanisms of the human FGF21 gene at the transcriptional level. A deletion study of the
human FGF21 promoter (21672 to +230 bp) revealed two fasting signals, including peroxisome proliferator-activated
receptor a (PPARa) and glucagon signals, that independently induced human FGF21 gene transcription in mouse primary
hepatocytes. In addition, two feeding signals, glucose and xylitol, also dose-dependently induced human FGF21 gene
transcription and mRNA expression in both human HepG2 cells and mouse primary hepatocytes. FGF21 protein expression
and secretion were also induced by high glucose stimulation. The human FGF21 promoter (21672 to +230 bp) was found
to have a carbohydrate-responsive element at 2380 to 2366 bp, which is distinct from the PPAR response element (PPRE).
Knock-down of the carbohydrate response element binding protein by RNAi diminished glucose-induced human FGF21
transcription. Moreover, we found that a region from 2555 to 2443 bp of the human FGF21 promoter region exerts an
important role in the activation of basic transcription. In conclusion, human FGF21 gene expression is paradoxically and
independently regulated by both fasting and feeding signals. These regulatory mechanisms suggest that human FGF21 is
increased with nutritional crisis, including starvation and overfeeding.
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Introduction
Fibroblast growth factor 21 (FGF21), a newly identified member
of the FGF19 subfamily, has recently emerged as a metabolic
hormone involved in the regulation of glucose and lipid
metabolism in mice [1–8]. In particular, FGF21 is induced in
the liver by fasting and regulates gluconeogenesis, fatty acid
oxidation, ketogenesis and torpor in mice [2,4,7]. In addition,
FGF21 stimulates glucose uptake in adipocytes and protects from
diet-induced obesity and metabolic disorders in obese or diabetic
animals given FGF21 and in FGF21 transgenic mice [2,3,5,8].
Relatively little is known about the regulation of FGF21 in
humans as compared to mice. In a human study, fasting for 7 but
not 2 days was found to induce FGF21 [9]. On the other hand,
some human studies have shown that serum FGF21 levels are
increased in both obese individuals and patients with type 2
diabetes, which suggest that hyperglycemia and/or hyperinsulin-
emia can regulate FGF21 gene expression in humans [10,11]. In
the present study, we show that human FGF21 gene expression
was regulated by glucose via ChREBP. In addition, two fasting
signals, PPAR a and glucagon also increased human FGF21 gene
transcription. Thus, this study helps to clarify the paradoxical
regulation of human FGF21 by both fasting and overfeeding, and
provides clues to understand the potential roles of FGF21 in
humans.
Materials and Methods
Construction of plasmid vectors
PCR was performed with an Expand High-Fidelity PCR system
(Roche) and the appropriate primers (Invitrogen). Luciferase gene
constructs containing 21672 to +230 bp of the human FGF21
promoter (pFGF21-1.6k) reporter vector and a series of 59-deletion
mutant vectors (pFGF21-1k, pFGF21-555, pFGF21-443, pFGF21-
289 and pFGF21+11) were prepared from human genomic DNA
and pGL4.12 vectors (Promega). The sequence of mouse short
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reported by Dentin et al. was used as a suitable sequence for RNAi
targeting [12]. Double-stranded oligonucleotides encoding
ChREBP or LacZ were synthesized, annealed and cloned into a
pEnter/U6 entry vector (Invitrogen).
Cell culture
Primary hepatocytes were isolated from normal male ddy mice
(20–25 g; Japan SLC) by using a collagenase perfusion method as
described previously [13]. The University of Tokushima Animal
Use Committee approved the study, and mice were maintained
according to the National Institutes of Health guidelines for care
and use of laboratory animals (approval ID, 08052). Hepatocyte
suspensions were plated on 35-mm plastic dishes in a final volume
of 2 ml of William’s E medium (Sigma) supplemented with 1 nmol
of insulin (Sigma), 1 nmol of dexamethasone (Sigma), 10% (v/v)
fetal bovine serum (Invitrogen) and 1% (v/v) penicillin/strepto-
mycin (Sigma). After 6 h of attachment, the medium was removed
and fresh, serum-free medium was added. After 12 h in culture,
the cells were stimulated for the indicated time with medium
containing glucose, xylitol or mannitol.
Human hepatoma HepG2 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Sigma) containing 10% (v/v)
fetal bovine serum, 50 IU/ml penicillin, and 50 mg/ml strepto-
mycin. After 12 h in culture with serum-free DMEM, the cells
were stimulated with medium containing glucose for the indicated
time.
Transfections and luciferase assays
Transfection studies were carried out in precultured mouse
primary hepatocytes or HepG2 cells. The indicated amount of
each expression plasmid was transfected simultaneously with a
luciferase reporter plasmid (0.5–1.0 mg) and pCMV-b-galactosi-
dase (0.25–0.5 mg, Invitorgen) by using Lipofectamin2000 (Invi-
trogen). The total amount of DNA in each transfection was
adjusted to 1.5 mg/well with pCMV. After 12 h, the cells were
cultured with medium containing glucagon, Forskolin, Wy-14643,
glucose, xylitol or mannitol for 6 h, and the amount of luciferase
activity in transfectants was measured and normalized to the
amount of b-galactosidase activity as measured by a standard kit
(Promega). Short hairpin ChREBP and the LacZ expression
vector (0.5 mg) were transfected 48 h prior to starting the luciferase
assay. Transfection efficiency was 4865% for primary hepatocytes
and 5268% for HepG2 cells. There was no significant difference
in the transfection efficiency between the cells.
RNA preparation and quantitative RT-PCR
Extraction of total RNA, cDNA synthesis and real-time PCR
analysis were performed as described previously [13]. The following
primers were used for quantitative PCR. b-actin (human): forward,
59-GGCACCACACCTTCTACAATGAGC-39; and reverse, 59-
AGCCTGGATAGCAACGTACATGGC-39. b-actin (mouse): for-
ward, 59-CTGACCCT GAAGTACCCCATTGAACA-39;a n d
reverse, 59-CTGGGGTGTTGAAGGTCTCAAACATG-39.F G F -
21 (human): forward, 59-GGGAGTCAAGACATCCAGGT-39;a n d
reverse, 59-GGCTTCGGACTGGTAAACAT-39. FGF21 (mouse):
forward, 59-CTACCAAGCATA CCCCATCC-39; and reverse,
59-GCCTACCACTGTTCCATCCT-39. L-pk:f o r w a r d ,5 9-CT-
GCCTTCTGGATATCGACT-39; and reverse, 59-GAGTCGT-
GCAATGTTCATCC-39. Fasn: forward, 59-CTGCAGAGAAGC-
GAGCATAC-39; and reverse, 59-CTTCTGCC AGTGAGTT-
GAGG-39. The relative abundance of each target transcript was
calculated by normalization to the amount of product amplified from
constitutively expressed b-actin mRNA.
Protein extraction, immunoblot analysis, and ELISA
The cultured hepatocytes and HepG2 cells were lysed by buffer
A (10 mM HEPES-KOH [pH 7.8], 0.1 mM EDTA, 5 mM KCl,
0.1% NP40) containing protease inhibitor. After centrifugation at
13,2006 g for 5 min at 4uC, the supernatant was collected as a
cytosol extract. The pellet was suspended by buffer C (50 mM
HEPES-KOH [pH 7.8], 0.1 mM EDTA, 420 mM KCl, 5 mM
MgCl2, 20% glycerol) containing protease inhibitor. After
centrifugation at 13,2006 g for 10 min at 4uC, the supernatant
was collected as a nuclear extract. Immunoblotting were
performed with antibodies against ChREBP (Novus Biologicals),
FGF21 (Abnova), b-actin (Sigma) and LaminB (Santa Cruz
Biotechnology). Isolated mouse primary hepatocytes were plated
in 6-well plate and stimulate indicated dose of glucose. The
cultured media was subjected to analysis for FGF21 concentration
with FGF21 ELISA kit according to the manufacturer’s instruc-
tions (R & D systems).
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays were performed as
previously described [14]. In brief, double-stranded oligonucleo-
tide probes for the human FGF21 carbohydrate response element
(ChoRE) were generated, annealed and labeled with [c
32-P]ATP.
The labeled probes were incubated with hepatic nuclear extracts
and 2 mg of poly (dI-dC) in binding buffer. The DNA-protein
complexes were resolved on a 5% polyacrylamide gel at 150 V for
90 min. The gels were dried and visualized by bioimage analyzer
(FLA9000, Fuji Photo Film).
Statistical analyses
All values are expressed as mean 6 SE. The significance of
differences was assessed between two groups by using unpaired
two-tailed t-tests, and among more than two groups by using
ANOVA or the Kruskal-Wallis test. When a significant difference
was found by ANOVA or the Kruskal-Wallis test, post hoc
analyses were performed by using the Tukey-Kramer protected
least significant difference test. Concentration-dependent effects
were found by using regression analysis. Differences were
considered significant at p,0.05. Statistical analyses were
performed by using StatView (version 5.0-J for Windows, SAS
Institute, Inc., Cary, NC).
Results
Glucose and xylitol induces FGF21 gene expression
Increases in serum FGF21 have been reported in obese and/or
impaired glucose tolerance patients; however, it is unclear whether
glucose can activate human FGF21 gene expression. Excess
glucose flux promotes the formation of ATP and xylulose-5-
phosphate (Xu-5-P) by glycolysis and the hexose monophosphate
shunt pathway. We previously showed that glucagon, which
increases the AMP/ATP ratio, stimulates FGF21 gene expression
in rat primary hepatocytes [13]. In this study, we focused on Xu-5-
P, which activates ChREBP via phosphatase 2A (PP2A) and
promotes its nuclear localization and DNA binding. Lpk and Fasn
are well-known to be glucose-response genes targeted by ChREBP
[15]. We therefore used Lpk and Fasn as positive controls in our
experiments.
Glucose dose-dependently induced FGF21 gene and protein
expression in HepG2 cells (Fig. 1A, B). This induction was also
observed in mouse primary hepatocytes stimulated by glucose and
xylitol, which are metabolized to Xu-5-p (Fig. 1C). Glucose
stimulation also increased secretion of FGF21 into the cultured
media (Fig. 1D). Glucose and xylitol also induced Lpk and Fasn
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mannitol could not stimulate this gene expression despite having
the same osmolarity (Fig. 1C). These results indicate that xylitol
can also induce glucose-responsive genes, as reported in an earlier
study [16]; therefore, xylitol was used for the subsequent
experiments in addition to glucose.
Both fasting and feeding signals induce human FGF21
promoter activity
To investigate further the mechanisms underlying the induction
of human FGF21 gene expression by glucose, we constructed
luciferase reporter vectors containing a series of 59-deletions in the
human FGF21 promoter. It has been reported that the human
FGF21 promoter has a putative peroxisome proliferator-activated
receptor (PPAR) response element (PPRE) in the 2696 to
2685 bp region [17]. We confirmed that wy-14643, a PPARa
agonist, dose-dependently increased pFGF21-1.6k promoter
activity in mouse primary hepatocytes (Fig. 2A). This response
was seen in pFGF21-1k but not in the pFGF21-555 and pFGF21-
289 deletion mutant vectors (Fig. 2B). We also investigated the
effect of another fasting signal, glucagon-PKA, on human FGF21
transcriptional activity. The PKA activators glucagon and
forskolin significantly increased pFGF21-1.6k promoter activity
(Fig. 2C). This response was seen in pFGF21-555 and pFGF21-
443 but not in pFGF21-289 deletion mutant vectors (Fig. 2D).
Next, we investigated the effect of feeding signals, including
glucose and xylitol, on human FGF21 transcription. Glucose
increased pFGF21-1.6k promoter activity in HepG2 cells (Fig. 3A).
However, the basal reporter activity was 15-fold lower in HepG2
cells than in mouse primary hepatocytes (Fig. 3B). Glucose and
xylitol, but not mannitol, stimulated pFGF21-1.6k promoter
activity in mouse primary hepatocytes (Fig. 3C, D). We then
tested which region of the promoter is important for glucose-
dependent induction of the human FGF21 gene. Xylitol induced
approximately 7-fold activation in the pFGF21-1.6k, pFGF21-1k,
pFGF21-555 and pFGF21-443 deletion mutant vectors, but
induction was reduced to 3-fold in the pFGF21-289 mutant
vector (Fig. 3E). Glucose also induced activation by 2-fold in the
pFGF21-443 mutant vector, but the pFGF21-289 mutant vector
did not respond to glucose (Fig. 3F). Interestingly, the basal human
FGF21 transcriptional activity was dramatically reduced in the
pFGF21-443 deletion mutant vector as compared to the pFGF21-
555 deletion mutant vector both in mouse primary hepatocytes
and HepG2 cells (Fig. 3G, H). This reduction was regulated in a
glucose-independent manner. These data indicate that the human
FGF21 promoter has at least one carbohydrate responsive region
located at 2443 to 2289, and also an important region at 2555
to 2443 for basal transcriptional activity regulated in a glucose-
independent manner.
ChREBP binds to human FGF21 promoter regions
To investigate whether ChREBP can bind within the 2443 to
2289 bp region of the human FGF21 promoter, we performed an
electrophoretic mobility shift assay. Since the basal reporter
activity was 15-fold higher in mouse primary hepatocytes than in
HepG2 cells (Fig. 3B), we used mouse primary hepatocytes for the
Figure 1. Glucose and xylitol induced FGF21 gene expression in HepG2 and mouse primary hepatocytes. A: Changes in FGF21 gene
expression stimulated by the indicated dose of glucose for 6 h in HepG2. B: Changes in FGF21 protein abundance in HepG2 cells stimulated by
indicated dose of glucose for 24 h. C: Changes in FGF21, L-pk, and Fasn gene expression stimulated by 10 mM glucose (Glu), xylitol (Xyl) or mannitol
(Man) for 6 h in mouse primary hepatocytes. The relative mRNA amount for each gene treated with 5 mM of glucose (A), or NT (non-treatment)
(C) was set as 1.0. D: Changes in FGF21 concentration in the cultured media of mouse primary hepatocytes stimulated by 3 mM glucose (G3) or
25 mM glucose (G25) for indicated time. Data represent mean 6 SE (n=3). {: Concentration-dependent effects were observed by regression analysis,
p,0.05. *: p,0.05 as compared to NT, mannitol and G3 stimulation.
doi:10.1371/journal.pone.0022976.g001
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extract from xylitol-stimulated mouse primary hepatocytes con-
tained a larger amount of ChREBP protein as compared with
control nuclear extract (Fig. 4A,B). We found that the human
FGF21 promoter contained a putative carbohydrate responsive
element (ChoRE), composed of two imperfect E-boxes separated
by an 8-bp gap, at position 2380 to 2366 bp (Fig. 4C). Xylitol-
stimulated nuclear protein bound more strongly to the 2380 to
2366 bp region of the human FGF21 promoter as compared with
the control of non-stimulated nuclear protein (Fig. 4D). This
binding was suppressed by preincubation with a competitor, the
2146 to 2124 bp region of Lpk, or ChREBP antibody (Fig. 4D).
These results are consistent with the results of transcriptional
activity evaluated by xylitol stimulation.
ChREBP is needed to induce FGF21 gene transcription by
glucose
To assess the effects of ChREBP on transcription of the human
FGF21 gene, we used a short hairpin RNA interference approach
to inhibit ChREBP gene expression. After transfection of the
pEnter-shChREBP vector, ChREBP gene expression and protein
abundance were effectively reduced in mouse primary hepatocytes
as compared to the control transfection (pEnter-shLacZ; Fig. 5A,
B). Treatment with shChREBP diminished the glucose-induced
upregulation of the human FGF21 promoter activity observed in
shLacZ-transfected cells (Fig. 5C). These results clearly show that
ChREBP is needed to induce human FGF21 gene expression by
glucose stimulation.
Discussion
In the present study, we examined the mechanisms regulating
the human FGF21 gene. We found that expression of the human
FGF21 gene is paradoxically regulated by both fasting and feeding
signals (Fig. 6A). Two fasting signals, including PPARa and
glucagon-PKA, increased expression of the human FGF21 gene.
Surprisingly, glucose and xylitol, which are feeding signals, also
induced human FGF21 gene expression through ChREBP
activation. The human FGF21 promoter has at least one
glucose-responsive region in the region 2380 to 2366 bp. In
addition, the human FGF21 basal transcriptional activity was
found to be independent of glucose, PPARa and glucagon-PKA.
It has been reported that fasting-induced liver FGF21 gene
expression is predominantly regulated by PPARa in mouse [4,17].
PPARa knockout mice, however, can increase FGF21 mRNA by
fasting [4]. We previously showed that another fasting signal,
Figure 2. Wy-14643, glucagon and forskolin induced FGF21 gene transcription in mouse primary hepatocytes. A: Changes in relative
luciferase activity of a pFGF21-1.6k reporter vector containing the 21672 to +230 bp region of the human FGF21 promoter simulated by indicated
dose of wy-14643 for 6 h in mouse primary hepatocytes. B: Schematic representation of 59-deletion mutants of the human FGF21 promoter and
changes in relative luciferase activity after stimulation with or without 10 mM wy-14643 for 6 h. C: Changes in relative luciferase activity of the
pFGF21-1.6k reporter vector stimulated by 10
27 M glucagon or 10
26 M forskolin (FSK) for 6 h in mouse primary hepatocytes. D: Schematic
representation of 59-deletion mutants of the human FGF21 promoter and changes in relative luciferase activity after stimulation with or without
10
27 M glucagon. The relative luciferase activity treated with DMSO (A), or NT (non-treatment) (C) was set as 1.0. For deletion experiments (B and D),
the relative luciferase activity of each deletion constructs treated with DMSO (B) or control (D) was set as 1.0. Data represent mean 6 SE (n=3).
{: Concentration-dependent effects were observed by regression analysis, p,0.05. *: p,0.05 as compared to DMSO or NT.
doi:10.1371/journal.pone.0022976.g002
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hepatocytes [13]. Here, glucagon and forskolin, a PKA activator,
significantly increased human FGF21 promoter activities (Fig. 2C).
This response was also seen in a PPRE deletion mutant vector,
suggesting that human FGF21 transcription is independently
regulated by both PPARa and glucagon-PKA signaling. In the
present study, we found that these fasting-induced mechanisms of
FGF21 regulation are conserved in the human FGF21 promoter.
We also showed that the human FGF21 promoter has one ChoRE
in a different region from the PPRE. The human FGF21 promoter
activities were dose-dependently increased by glucose or xylitol
stimulation, as well as by a PPARa agonist (Fig. 2A, 3B and data
not shown). Some human studies have reported that serum FGF21
concentrations are upregulated by fenofibrate [9]. In addition, as
compared to normal glucose-tolerant subjects, plasma FGF21
levels were found to be higher in obese and IGT subjects [10].
These data suggest that hepatic FGF21 mRNA expression is
regulated, in part, through glucose, as well as in a PPARa-
dependent manner, and this regulation can be reflected in serum
FGF21 concentrations in humans.
Recently, Iizuka and colleagues reported that glucose can
induce FGF21 gene expression in rat primary hepatocytes [16].
They also showed that the mouse FGF21 promoter has a putative
ChoRE in the 274 to 252 bp region. In contrast, we identified a
glucose-response region located at 2380 to 2366 bp in the
human FGF21 promoter. A typical ChoRE comprises two E-boxes
separated by a 5-bp space, as observed in the mouse FGF21
promoter [16]; however, in humans the ChoRE comprises two
imperfect E-boxes, separated by an 8-bp space at 2380 to 2366.
The space between the two E-boxes is important because a
spacing of 4 bp between the CACGTG E-box motifs has been
shown to result in a complete loss of induction [18]. By contrast,
spacing of 6, 7 and 15 bp leads to a weak but significant response
to glucose [18], indicating that the human FGF21 promoter has a
Figure 3. Glucose and xylitol induced human FGF21 gene transcription in mouse primary hepatocytes and HepG2 cells. A: Changes
in relative luciferase activity of the pFGF21-1.6k reporter vector stimulated by indicated dose of glucose for 24 h in HepG2 cells. B: Basal luciferase
activity of the pFGF21-1.6k reporter vector in mouse primary hepatocytes (Mpl) and HepG2 cells. C: Changes in relative luciferase activity of the
pFGF21-1.6k reporter vector stimulated by 10 mM glucose (Glu), xylitol (Xyl) or mannitol (Man) for 6 h in mouse primary hepatocytes. D: Changes in
relative luciferase activity of the pFGF21-1.6k reporter vector stimulated by the indicated dose of xylitol for 6 h in mouse primary hepatocytes. E, F:
Schematic representation of 59-deletion mutants of the human FGF21 promoter and changes in relative luciferase activity after stimulation with or
without 20 mM xylitol (E) or 20 mM glucose (F). G, H: Basal luciferase activities of 59-deletion mutants of the human FGF21 promoter in mouse
primary hepatocytes (G) and HepG2 cells (H). The relative luciferase activity for C through F was expressed as described in the Figure 2. For basal
luciferase activity analysis (G and H), the relative luciferase activity of -1672 bp was set as 1.0. Data represent mean 6 SE (n=3). {: Concentration-
dependent effects were observed by regression analysis, p,0.05. *: p,0.05 as compared to the control.
doi:10.1371/journal.pone.0022976.g003
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the region from 2555 to 2443 bp of the human FGF21 promoter
region exerts an important role in activation of basic transcription.
This region is separate from the PPRE, ChoRE and glucagon-
PKA responsive elements.
In the present study, we showed that the human FGF21
transcriptional activity is regulated by both fasting and feeding
signals. A recent study demonstrated that one-week prolonged
fasting stimulation was required to increase FGF21 levels in
humans [9]. Moreover, another human study reported that
superphysiological levels of FFAs were required to induce
FGF21 in vivo [19]. These observations suggest that FGF21 is
upregulated by nutritional crisis. On the other hand, most human
studies have linked obesity or IGT with increased FGF21 levels in
Figure 4. The human FGF21 promoter has a putative carbohydrate-responsive element. A, B: Changes in ChREBP protein abundance in
cytosolic and nuclear fractions from mouse primary hepatocytes stimulated by 10 mM xylitol for 6 h. C: Putative carbohydrate responsive element
(ChoRE) in the human FGF21 promoter. D: An electrophoretic mobility shift assay was performed with the mouse primary hepatocyte nuclear fraction
stimulated by xylitol (X) or not (NT). We used a putative ChoRE (2380 to 2366 bp; lanes 1–5). Factor C is a competitor (L-pk; 2142 to 2124 bp) and
Ab is ChREBP antibody. Arrow indicates DNA and protein complex. Data represent mean 6 SE (n=3). *: p,0.05 as compared to NT (non-treatment).
doi:10.1371/journal.pone.0022976.g004
Figure 5. ChREBP is needed to induce FGF21 gene transcription by glucose. A, B: Changes in relative ChREBP gene expression and protein
abundance at 48 h after transfection of either shLacZ or shChREBP vector in mouse primary hepatocytes. C: Changes in relative luciferase activity of
the human 21.6 kb FGF21 reporter vector stimulated by 20 mM glucose 48 h after transfection of either shLacZ or shChREBP vector in mouse
primary hepatocytes. The relative mRNA expression and protein abundance of ChREBP transfected with shLacZ vector was set as 1.0. The relative
luciferase activity of NT (non-treatment) was 1.0. Data represent mean 6 SE (n=3). * p,0.05 as compared to shLacZ or NT.
doi:10.1371/journal.pone.0022976.g005
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have more problems with over-nutrition than with starvation.
These results indicate that the human FGF21 levels are increased
in such abnormal physiological conditions. In fact, the responsivity
of human FGF21 to glucose stimulation is weak, and the serum
FGF21 levels of healthy subjects show no major changes related to
feeding and fasting over the course of a day [9].
Our result suggests that FGF21 levels in human may be
increased under malnutrition conditions, however Dosta ´lova ´e ta l
found that plasma FGF21 levels were lower in anorexic patients
than control subject [20]. In contrast, Fazeli et al reported that
FGF21 levels in anorexia nervosa patient were higher than those
of control subjects after multiple adjustments including percent
body fat [21]. They also mentioned that the balance of liver-
derived FGF21 and adipose-derived FGF21 should be considered,
because anorexic patients have extremely lower fat mass than
healthy people. Additional studies are needed to elucidate the
regulation and role of FGF21 in anorexia patients.
In addition, FGF21 play an important role in the adipocytes.
FGF21 can stimulate glucose uptake and triglyceride degradation
in the adipose tissue. FGF21 has been shown to be up-regulated
during adipocyte differentiation [11]. ChREBP has also been
shown to be up-regulated by adipocyte differentiation as well as
glucose stimulation [22]. These inductions were also seen in
PPARc agonist stimulation. It seems that PPARc and ChREBP
can coordinately regulate FGF21 gene expression in adipocytes.
However, additional studies are needed to investigate whether
ChREBP directly and/or independently regulate FGF21 gene
expression in the adipocytes to understand the role of FGF21 under
over-nutrition or malnutrition observed in anorexic patients.
In conclusion, the human FGF21 gene was paradoxically found
to increase following both fasting and feeding signals in HepG2
and mouse primary hepatocytes. This unique dual regulation
might be seen as paradoxical, and suggest that human FGF21 is
increased with nutritional crisis, including starvation and over-
feeding (Fig. 6B). Thus, human FGF21 levels may well be a useful
marker to determine our nutritional status.
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